Developing methods for multi-omic data integration and utilisation in pharmaco-genetic and -genomic analysis of drug responders and non-responders
Lead Research Organisation:
Imperial College London
Department Name: National Heart and Lung Institute
Abstract
Asthma is a chronic inflammatory disease of the airway that mostly responds to topical corticosteroids. However, 5-10% of patients have severe disease that fails to respond well to treatment. This bioinformatic project utilise multi-omic data obtained from the pan-European U-BIOPRED severe asthma cohort to investigate the role of the microbiome in directing biological processes associated with subtypes of severe asthma whilst the second project uses network fusion and other approaches to merge different omics datasets and investigate drug responses. The project will involve state-of-the-art bioinformatics approaches to analyse metagenomic, genetic, transcriptomic, proteomic and metabolomics data stored within the TransMart KM system
People |
ORCID iD |
Ian Adcock (Primary Supervisor) |
Publications
Ali MK
(2020)
Crucial role for lung iron level and regulation in the pathogenesis and severity of asthma.
in The European respiratory journal
Kermani NZ
(2021)
Sputum ACE2, TMPRSS2 and FURIN gene expression in severe neutrophilic asthma.
in Respiratory research
Tiotiu A
(2021)
Sputum macrophage diversity and activation in asthma: Role of severity and inflammatory phenotype.
in Allergy
Studentship Projects
Project Reference | Relationship | Related To | Start | End | Student Name |
---|---|---|---|---|---|
BB/R505663/1 | 06/11/2017 | 05/11/2021 | |||
1958049 | Studentship | BB/R505663/1 | 06/11/2017 | 05/11/2021 |
Description | My research has potential for translational impact; addressing therapy needs of severe asthmatics and airway disease patients. Asthma is hetergenous, most therapies are developed for the majority of sufferers. Here we have possibly identified a number of novel therapies for those suffering from non-mainstream severe asthma subtypes and furthermore we have phenotyped the specific types of asthma patients that may be candidates for these drugs. |
Exploitation Route | Clinical trials and animal model studies of the novel therapies for asthma we have identified with specific pre-selection of asthma patients in accordance with the phenotypes of potential responders we have identified. |
Sectors | Healthcare Pharmaceuticals and Medical Biotechnology |
URL | https://erj.ersjournals.com/content/54/suppl_63/OA1606 |
Description | Investigated potential of novel anti-IL22 biologic with Prof. Emma Guttman and her lab at Mount Sinai, NYC |
Organisation | Icahn School of Medicine at Mount Sinai |
Country | United States |
Sector | Academic/University |
PI Contribution | My PI Prof. Ian Adcock and industrial PhD supervisor, at the time, John Riley (GSK, Stevenage) secured funding for me to undertake a 3 month research collaberation with the Ichann School of Medicine, Mount Sinai Hosptial, NYC. I collaberated with the lab of Prof. Emma Guttman to learn bioinformatics methods to computationally investigate potential use of an anti-IL22 drug in asthma. This drug had been trialed successfully in atopic dermatits and I obtained drug response gene signatures from good clinical responders from their data and performed studies to identify and phenotype asthma patients which are elevated in these gene signatures. |
Collaborator Contribution | I was hosted by the lab of Prof Emma Guttman and her team at the Ichann School of Medicine, Mount Sinai Hosptial, NYC. I was encouraged to expand my understanding of inflammatory diseases by attending lectures. I was directly supervised by a bioinformatics specialist (Dr Ana Pavel Brandusa) and learned a great deal from her mentoring. |
Impact | Currently one European Resp. Journal abstract: Is Fezakinumab, an anti-IL22 antibody, a putative novel therapy for a subset of severe asthma? Yusef Badi, Ana B Pavel, John H Riley, Kian F Chung, Emma Guttman-Yassky, Ian M Adcock European Respiratory Journal Sep 2019, 54 (suppl 63) OA1606; DOI: 10.1183/13993003.congress-2019.OA1606 Yes, this involves computational biology / biostatistics, clinical medicine research, airway disease, dermatology. |
Start Year | 2018 |